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Abstract
Background: The aims of this study were to determine the prevalence of the different anti-erythrocytic
alloantibodies, to describe pregnancy outcomes according to a low-risk and high-risk classification for fetal anemia
and to determine the factors that influence adverse perinatal outcomes.
Methods: This retrospective observational study included women referred to our center following the identification
of maternal anti-erythrocytic alloantibodies between 2002 and 2017. Pregnancies were classified as high risk for
fetal anemia in cases with clinically significant antibodies, no fetal-maternal compatibility and titers ≥1:16 or any
titration in cases of Kell system incompatibility. In high-risk pregnancies, maternal antibody titration and the fetal
middle cerebral artery peak systolic velocity (MCA-PSV) were monitored. Low-risk pregnancies underwent routine
pregnancy follow-up.
Results: Maternal antibodies were found in 337 pregnancies, and 259 (76.9%) of these antibodies were clinically
significant. The most frequent antibodies were anti-D (53%) and anti-K (19%). One hundred forty-three pregnancies
were classified as low risk for fetal anemia, 65 (25%) cases were classified as no fetal-maternal incompatibility, 78
had clinically nonsignificant antibodies, 4 (2.8%) resulted in first-trimester pregnancy loss, and 139 (97.2%) resulted
in livebirths. Of the 194 high-risk pregnancies, 38 had titers < 1:16 (resulting in 38 livebirths), and 156 had titers ≥1:
16 or anti-K antibodies. In the last group, 6 cases miscarried before 18 weeks, 93 had a MCA-PSV < 1.5 multiples of
the median (MoM), resulting in 3 perinatal deaths that were unrelated to fetal anemia, one termination and 89
livebirths; and 57 had a MCA-PSV > 1.5 MoM, resulting in 3 intrauterine deaths, 6 terminations and 48 livebirths.
Ninety-two intrauterine transfusions were performed in 45 fetuses (87% anti-D). Adverse outcomes were related to
a MCA-PSV > 1.5 MoM (p < 0.001), hydrops (p < 0.001) and early gestational age at first transfusion (p = 0.029)
Conclusion: Anti-D remains the most common antibody in fetuses requiring intrauterine transfusion. A low or
high-risk classification for fetal anemia based on the type of antibody, paternal phenotype and fetal antigen allows
follow-up of the pregnancy accordingly, with good perinatal outcomes in the low-risk group. In the high-risk group,
adverse perinatal outcomes are related to high MCA-PSV, hydrops and early gestational age at first transfusion.
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Background
Hemolytic disease of the fetus and newborn is a rare but
life-threatening disease. Transplacental passage of ma-
ternal antibodies that bind to fetal erythrocyte antigens
of paternal origin lead to fetal or neonatal hemolysis. If
untreated, fetal anemia can lead to fetal heart failure,
hydrops or even death.
Although anti-D alloimmunization is the most com-
mon cause of hemolytic disease of the fetus and new-
born, more than 50 anti-erythrocytic alloantibodies are
involved [1, 2]. The importance and proportion of non-
anti-D antibodies increased [3] after the implementation
of pre- and postnatal anti-D prophylaxis.
Doppler ultrasound for peak systolic velocity (PSV)
measurement at the middle cerebral artery (MCA) al-
lows for better management of the disease, avoiding in-
vasive procedures for diagnosis of fetal anemia [4–6].
MCA-PSV measurements can detect all cases of fetal
anemia, with a false positive rate of 12% [7, 8].
On the other hand, the introduction of a diagnostic
test for the fetal genotype in amniotic fluid [9] and in
maternal blood for certain antigens [10–12] allows the
risk of fetal anemia to be ruled out in a nonnegligible
percentage of cases, and, therefore, alleviates the need
for thorough ultrasound-based follow-up.
The aims of this study are as follows: first, to deter-
mine the prevalence of different anti-erythrocytic alloan-
tibodies in our center and in pregnancies that required
an intrauterine transfusion; second, to describe the preg-
nancy outcome according to a low-risk or high-risk clas-
sification for fetal anemia; and third, to determine the
factors that influence adverse perinatal outcomes.
Methods
This is a retrospective observational cohort study includ-
ing women referred to our center following the finding
of maternal antibodies against fetal red blood cell (RBC)
antigens between 2002 and 2017. Exclusion criteria were
preconceptional counseling, positive result following
anti-D administration and twin pregnancies. All data
were recorded in an electronic database.
Clinical protocol
In Rh D-negative women, prophylaxis included 300 μg
(1500 IU) anti-D immunoglobulin administration at 28
weeks, after delivery if the neonate was Rh D-positive
and following any of these circumstances: an invasive
test, vaginal bleeding, external cephalic version, abdom-
inal trauma, miscarriage, ectopic pregnancy or termin-
ation of pregnancy.
Since 2008, for primary prevention of alloimmuniza-
tion in females of child-bearing age in our clinical prac-
tice, only Rh (D, C, c, E, e) and K compatible RBC units
have been transfused in fertile women.
The prevalence of Rh D-negative in our Maternal-
Fetal Medicine Unit is 15%, and the prevalence of Kell
positivity is 8% (according to our blood bank and trans-
fusion service).
Antenatal antibody screening was performed during
the first trimester of pregnancy in all pregnant women
and between 24 and 28 weeks only in Rh D-negative
women (prior to anti-D immunoglobulin administra-
tion). Red blood cell antibody screening and identifica-
tion was performed with the indirect antiglobulin test
(IAT) method in Gel Cards (Anti-human globulin DG
Gel®, Grifols, Spain). Antibody titration was determined
by preparing serial doubling dilutions of plasma and
testing them by IAT using reagent red cells showing het-
erozygous expression of the corresponding antigen(s). If
the IAT was positive, the titration was repeated every 4
weeks or every 2 weeks if a rapid increase was detected
and if the titer was close to 1:16.
Women were referred to our center following the find-
ing of maternal antibodies against fetal red blood cell an-
tigens. The type of antibody was identified, and the titer
was determined. For clinically significant antigens, first,
the paternal erythrocyte phenotype was determined. In
the case of anti-D, anti-c and anti-K antibodies, if the
father had a positive phenotype and was heterozygous,
the fetal genotype was determined in amniotic fluid or
maternal blood, depending on the period of the study.
The technique for fetal antigen-D genotyping in mater-
nal blood has been performed in our center since 2004
and that for antigen c and Kell has been performed since
2007 (Fig. 1). The fetal RhD genotype was performed
after 10 weeks of pregnancy, the Rhc genotype was per-
formed after 16–18 weeks, and the Kell genotype was
performed after 20 weeks of pregnancy. Fetal RhD geno-
typing was performed from cell-free fetal DNA in mater-
nal plasma by real-time quantitative PCR with TaqMan
probes for the detection of RhD exons 5 and 10. Fetal
Rhc or Kell genotyping was also carried out by real-time
quantitative PCR with allele-specific primers. All anti-
bodies belonging to the Rh system, Kell system, Duffy
system Fya and MNS system S antigen were considered
clinically significant antibodies.
Cases with fetal-maternal blood compatibility under-
went routine pregnancy care. The rest of the pregnant
women with unknown or fetal-maternal incompatibility,
with clinically significant antibodies, titers higher than 1:
16 or any titration in the case of Kell system incompati-
bility, were considered high risk for fetal anemia. In
these cases, weekly follow-up by ultrasound was per-
formed, assessing the MCA-PSV, amniotic fluid volume
and fetal signs of anemia or hydrops. No further IAT
was performed in these cases.
When the MCA-PSV was above 1.5 multiples of the
median (MoM) in two measurements taken 24 h apart,
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intrauterine fetal transfusion was performed if less than
34 weeks, and the baby was delivered at or after 34 weeks.
The transfusion procedure was always performed
under fetal immobilization with rocuronium or vecuro-
nium. The preferred vascular access site was the umbil-
ical vein in the portion of the umbilical cord near its
insertion into the placenta and, in exceptional cases, in
the intrahepatic umbilical vein. Prior to the transfusion,
a fetal blood sample was obtained to measure the fetal
hematocrit, which allowed us to calculate the number of
RBCs to be transfused. The blood was adequately pre-
pared as follows: type 0 Rh CDE negative, except in anti-
c cases, where the blood was Rh DCe; compatible with
maternal antibodies; negative for cytomegalovirus anti-
bodies; relatively fresh (< 7 days of age); subjected to leu-
kodepletion by filtration; irradiated; suspended in AB
plasma; and tightly packed to a final hematocrit of 75 to
85%. A second sample was obtained at the end of the
transfusion to measure the final hematocrit. MCA-PSV
was also used for the follow-up of the transfused fetuses.
The need and timing of the second and subsequent
transfusions was based on the values of MCA-PSV and
the expected decline in the fetal hematocrit, according
to the number of previous transfusions.
In transfused pregnancies, delivery was planned be-
tween 35 and 37 weeks depending on the intrauterine
transfusion interval and last transfusion. In pregnancies
where MCA-PSV was above 1.5 MoM beyond 34 weeks
the baby was delivered. In pregnancies at high risk for
anemia with normal MCA-PSV, delivery was planned
between 37 and 39 weeks.
Birth data and neonatal follow-up were recorded, in-
cluding postnatal treatment (phototherapy, immune
globulin therapy, RBC transfusion or neonatal exchange
transfusion) and additional complications. The indica-
tion for phototherapy was determined according to the
total serum bilirubin values at the specific hourly age of
the patient, gestational age at birth, and the presence or
absence of risk factors for hyperbilirubinemia. Immuno-
globulin therapy was indicated when the total serum
bilirubin level was rising despite intensive phototherapy
but did not meet the criteria for exchange transfusion.
Exchange transfusion was indicated in two circum-
stances: a) high total serum bilirubin values, using a
threshold specific to the hourly age of the patient, gesta-
tional age at birth and the presence or absence of risk
factors for hyperbilirubinemia; and b) a rise in the total
serum bilirubin level greater than 0.5 mg/dL per hour,
Fig. 1 Clinical protocol
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despite intensive phototherapy. RBC transfusion was in-
dicated in cases of hypovolemic shock or in cases where
hyperbilirubinemia and anemia were moderate.
Statistical analysis
All data were collected and entered anonymously into
an electronic database for further analysis.
For descriptive statistics, categorical data are reported
as frequencies and percentages and continuous variables
are described as medians and ranges.
Univariate logistic regression analysis was performed to
determine the factors related to adverse perinatal outcomes.
Results
Four hundred and one women were referred to our cen-
ter following the finding of maternal antibodies against
fetal red blood cell antigens. Sixty-four women were ex-
cluded from the study, 19 had been referred for precon-
ceptional assessment, 38 were false-positive cases or had
antibodies following the administration of anti-D
prophylaxis, and 7 were twin pregnancies cases.
The presence of maternal antibodies was confirmed in
337 pregnancies. Thirty-nine women were followed up
in more than one pregnancy (range: 2 to 4). In 259
(76.9%) pregnancies, clinically significant antibodies were
found. The distribution of antibodies is shown in Table 1.
Anti-D antibody was the most frequent clinically signifi-
cant antibody. Within the non-anti-D isolated anti-
bodies, the most frequent was anti-K followed by anti-E
and anti-c (Table 2). Multiple clinically significant anti-
bodies were found in 65 (19.3%) pregnancies.
In the group of women with clinically significant anti-
bodies, 65 (25.1%) had paternal compatibility or negative
fetal antigen and were classified as low risk (Fig. 1).
Pregnancy outcomes (Table 3)
From the 143 pregnancies with low risk for fetal anemia,
3 (2.1%) had a first-trimester miscarriage, 1 (0.7%) opted
for a termination of pregnancy at 14 weeks and 139
(97.2%) resulted in live births. One case with anti-S and autoantibodies (IgG) developed hydrops at 18 weeks and
required a single transfusion.
From the 194 pregnancies at high risk for fetal anemia,
6 (3.1%) resulted in a miscarriage or termination of preg-
nancy prior to 18 weeks, before the MCA-PSV could be
measured, although none of the cases had ultrasound
signs of fetal anemia.. Seven women (3.6%) opted for a
termination of pregnancy after 18 weeks; one case had
trisomy 21 without signs of fetal anemia, and six cases
had high MCA-PSV with one due to hepatitis C infec-
tion and five due to fetal brain lesions. Of these five, one
woman was referred at 26 weeks with fetal hydrops and
brain lesions (hypoxic-ischemic lesions confirmed by
magnetic resonance imaging) and decided to terminate
Table 1 Prevalence and distribution of anti-erythrocyte antibodies
Anti-erythrocyte antibodies Frequency (n = 337) (%)
Antibodies not leading to HDFNa 29 8.6
Antibodies rarely leading to HDFNb 48 14.2
Clinically significant antibodies: 259 76.9
• Anti D 138
• Non anti-D 121
Unidentified antibody 1 0.3
aanti-Lewis (n = 26), anti Chido (n = 1), anti-Jra (n = 1), anti P1 (n = 1)
banti-M (n= 28), ABO (n= 9), antibodies (n= 3), y anti-Jka (n= 4), anti Vel (n= 2),
anti- Lua (n= 2)
HDFN hemolytic disease of the fetus and newborn
Table 2 Distribution of clinically significant antibodies
Antibody specificities Frequency Percentage
Anti-D 138 53.3%
• D 90
• D + C 31
• D + E 2
• D + C + E 9
• D + G 1
• D + G + E 1
• D + other systems 4
Anti-K 49 18.9%
• K 47
• K + Rh (E) 2
Anti-c 20 7.7%
• c 17
• c + E 2
• c + K + Fya 1
Anti-E 27 10.4%
• E 22
• E + c 4
• E + s 1
Anti-C 7 2.7%
• C 4
• C + e 2
• C + Lea 1
Anti-e 5 1.9%
• e 3
• e + C 1
• e + S 1
Anti Cw 1 0.4%
Anti Fya 2 0.8%
Anti S 10 3.9%
Total 259 100
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the pregnancy without receiving any intrauterine transfu-
sion. The other four had received early RBC transfusions
at 19, 19, 21 and 24 weeks, and showed brain lesions on
ultrasound shortly after (four cases of brain hemorrhage).
Five cases of intrauterine deaths occurred; three had
undergone an intrauterine transfusion, and two had not.
Neither of these two fetuses had shown previous signs of
anemia; one case showed placental abruption at 30
weeks, and the other case, with a fetus without previous
intrauterine transfusion, .showed chorioamnionitis at 38
weeks. The other three cases were posttransfusional
deaths at 18, 22 and 26 weeks. One neonatal death oc-
curred during labor, after a difficult breach delivery, and
without previous signs of fetal anemia (Table 3).
Intrauterine transfusions
In 58 fetuses, MCA-PSV was above 1.5 MoM. Thirteen
of these cases did not receive a blood transfusion. In 11
cases that were more than 34 weeks’ of gestational age,
the babies were delivered, and in two cases, the women
opted for a termination of pregnancy (one with an active
hepatitis C infection and the other with brain hypoxic-
ischemic lesions).
Forty-five fetuses (13.4% of all fetuses and 23.2% of
those that were high risk for fetal anemia) received an
RBC transfusion, 39 fetuses (86.7%) had anti-D anti-
bodies, 2 fetuses (4.4%) had anti-c antibodies, 2 fetuses
(4.4%) had anti-Kell antibodies, 1 fetus (2.2%) had anti-E
antibodies, and 1 fetus (2.2%) had anti-S antibodies. The
need for a transfusion was highest in the group with
anti-D antibodies (28.3%), followed by the groups with
anti-c (10%) and anti-Kell antibodies (4.1%) (Fig. 2).
In one case, classified as low risk, the mother had both
anti-S antibodies and autoantibodies (IgG), and the
father was negative for S antigen. The fetus showed signs
of anemia (hydrops and MCA-PSV > 1.5 MoM) at 18
weeks, requiring a single transfusion (pretransfusional
hemoglobin 7.0 g/dL), and was delivered at 33 weeks
with a postnatal hemoglobin level of 19 g/dL.
Ninety-two intrauterine RBC transfusions were per-
formed in 45 fetuses. Twenty cases (44.4%) received a
single transfusion, 13 (28.9%) cases required two transfu-
sions, five (11.1%) cases required three transfusions, four
(8.9%) cases required four transfusions, and three (6.7%)
cases required five transfusions. All fetuses that required
three or more transfusions had their first transfusion be-
fore 24 weeks and had anti-D antibodies (Table 4).
Overall, the posttransfusional survival rate was 96.7% (89
out of 92 transfusions). Seven fetal losses occurred among
the transfused fetuses: three posttransfusional fetal deaths,
all of which had fetal hydrops and were transfused at 18, 22
and 26weeks, respectively, and four pregnancy terminations
before 24weeks due to fetal brain lesions (Table 4). Two
women underwent posttransfusional emergency cesarean
Table 3 Pregnancy outcomes according to the group of risk
Clinically nonsignificant
antibodies (n = 78)
Clinically significant antibodies (n = 259)
Paternal compatibility
or negative fetal
antigen (n = 65)
Not compatible, fetal unknown or positive fetal antigen (n = 194)
Titer< 1:16 (n = 38) Titer> 1:16 or anti-Kell (n = 156)
Low risk High risk
Miscarriage or TOP < 18 weeks 2 (2.6%) 2 (3.1%) 0 6 (3.8%)
Normal MCA-PSV
(n = 93)
Abnormal MCA-PSV
(n = 57)
Termination of pregnancy ≥18
weeks
0 0 0 1 (1.1%) 6 (10.5%)
Perinatal death 0 0 0 3 (3.2%) 3 (5.3%)
Livebirth 76 (97.4%) 63 (96.9%) 38(100%) 89 (95.7%) 48 (84.2%)
Intrauterine transfusion 0 1 (1.5%) 0 0 44 (77.2%)
Gestational age at birth 39.0 (27.0–42.0) 39.0 (33.0–41.0) 38.0 (26–41) 37.2 (26–42) 34.0 (27–38)
Categorical data are shown as the frequency (percentage), and continuous data are shown as the median (range)
MCA-PSV Middle cerebral artery peak systolic velocity
Fig. 2 Abnormal peak systolic velocity at the middle cerebral artery
(dark gray) and transfusions (clear gray) in pregnancies with clinically
significant antibodies
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sections: one at 27 weeks due to sustained fetal bradycardia
and the other at 34 weeks due to placental abruption. The
median gestational age at delivery in this group was 34
weeks (range: 27–37), and 60.5% (23 of 38) of women
underwent a cesarean section.
Nine (20%) of the 45 transfused fetuses had fetal
hydrops prior to the first transfusion. Of these, 4 (44.4%)
cases resulted in livebirths, 3 (33.3%) cases resulted in
posttransfusional deaths, and 2 (22.2%) cases opted for
termination of pregnancy. Of the 36 nonhydropic trans-
fused fetuses, 34 (94.4%) resulted in livebirths, and 2
(5.6%) opted for a termination of pregnancy.
Adverse perinatal outcomes were significantly associ-
ated with a MCA-PSV > 1.5 MoM (OR, 9.282, 95% CI
2.99 to 28.84, p < 0.001), hydrops (OR 20.6, 95% CI 4.90
to 86.57, p < 0.001) and gestational age at first transfu-
sion (OR 0.73, 95% CI 0.55 to 0.97, p = 0.029).
Neonatal outcome
Data for neonatal outcomes were obtained for 304 of the
314 livebirths (96.8%). Neonatal treatment according to
the risk group is summarized in Table 5.
Among the transfused fetuses, out of 38, 38 (100%) re-
quired phototherapy, 19 (50%) required immunoglobulin
therapy, 21 (55.2%) required RBC transfusion, and 24
(63.2%) underwent exchange transfusion.
Discussion
This report presents several findings. First, anti-D
remains the most frequent antibody, and anti-D is asso-
ciated with the highest risk for fetal anemia and a need
for intrauterine transfusion, and non-anti-D antibodies
account for 13% of transfused fetuses. Second, a classifi-
cation of the risk of anemia as high or low based on the
type of antibody, paternal phenotype, fetal antigen and
antibody titration permits routine follow-up for the low-
risk groups, reducing costs and maternal anxiety, with
good perinatal and neonatal outcomes. On the other
hand, pregnancy surveillance of high-risk groups in-
cludes intensive monitoring, with regular measurements
of the MCA-PSV. Adverse outcomes in this group were
related to high MCA-PSV, hydrops and early gestational
age at first transfusion. Third, there was no need for
neonatal RBC transfusion or exchange transfusion in
low-risk pregnancies or pregnancies with titers under 1:
16. In the high-risk group with titers of 1:16 or higher, a
normal MCA-PSV could not rule out the presence of
mild or moderate anemia that might require neonatal
treatment. In our series 53% of the antibodies were anti-
D, 19% were anti-K, 8% were anti-c, and 10% were anti-
E. Other studies found a lower prevalence of anti-D anti-
bodies (12.5%) and a similar prevalence of anti-K (8%)
[13, 14]. The data by Awowole et al were obtained from
the blood bank and transfusion service, and the data by
Bollason et al. were obtained from the national birth
registry, which collects data for all red cell antibodies. In
our case, these figures might be biased and probably do
not reflect the real prevalence in our population since
women are more likely to be referred in cases of clinic-
ally significant antibodies.
The transfusion rate in our study is slightly higher
than that reported by Awowole et al. (13.4% versus
7.3%), but this might also be explained by a bias in the
denominator of our study, as previously mentioned.
Table 4 Pregnancy outcome according to gestational age at first transfusion
Gestational age at first transfusion n Perinatal death TOP Livebirths Number of intrauterine transfusions
< 20 weeks 6 1 (16.7%) 2 (33.3%) 3 (50%) 2.5 (1–4)
21–24 weeks 8 1 (12.5%) 2 (25.0%) 5 (62.5%) 4.5 (4–5)
25–28 weeks 15 1 (6.7%) 0 14 (93.3%) 2 (1–3)
> 28 weeks 16 0 0 16 (100%) 1 (1–3)
Categorical data are shown as the frequency (percentage), and continuous data are shown as the median (range)
TOP Termination of pregnancy
Table 5 Neonatal treatment according to the risk group
Clinically
nonsignificant
antibodies
(n = 65)
Clinically significant antibodies
Compatible or negative
fetal antigen (n = 63)
Titer < 1:16
(n = 38)
Titer > 1:16, Normal
MCA-PSV (n = 90)
Titer > 1:16, Abnormal
MCA-PSV (n = 48)
Low risk High risk
Phototherapy 2/65 (3.1%) 1/63 (1.6%) 1/38 (2.6%) 53/90 (58.9%) 47/48 (97.9%)
Immunoglobulin therapy 0/64 0/62 0/38 25/90 (27.8%) 22/31 (71.0%)
Transfusion 0/64 0/63 0/38 11/90 (12.2%) 24/41 (58.5%)
Exchange transfusion 0/65 0/63 0/38 14/90 (15.6%) 27/48 (56.3%)
MCA-PSV Middle cerebral artery peak systolic velocity
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However, the distribution of antibodies among the trans-
fused women was very similar to those of other studies
in which approximately 85% of the transfused fetuses
had anti-D antibodies [15–17].
The transfusion need and perinatal outcome are re-
lated to the type of antibody, with RhD isoimmunization
being the most frequent and most serious during preg-
nancy. In our series, 46.7% of pregnancies with clinically
significant antibodies were non anti-D antibodies, the
most frequent being c, E and Kell antibodies. In
addition, 13% of the transfused fetuses belonged to this
group. This fact reinforces the idea of the need to per-
form an IAT for all pregnant women, not only for those
who are RhD negative. In our study, 4.4% of the trans-
fused fetuses belonged to the Kell system group, which
was somewhat low compared to the percentage de-
scribed in the literature [7].
The MCA-PSV measurement remains the method of
choice to follow up pregnancies at risk of fetal anemia. It
is an innocuous, inexpensive technique with a good cor-
relation in determining the optimal time to perform intra-
uterine transfusion of packed RBCs. Although it loses
sensitivity after 35 weeks and in poly-transfused fetuses, it
is still the method used in our center, together with cardi-
otocographic record monitoring from 28 to 30 weeks, to
assess fetal anemia. Early detection of fetal anemia, before
fetal hydrops development, results in a very good survival
rate. However, it is important to note that the MCA-PSV
is useful to detect cases with severe anemia requiring a
transfusion but does not exclude the presence of mild or
moderate anemia that may require neonatal treatment.
Correct pregnancy surveillance allows optimally plan-
ning in terms of the time and place of delivery, even for
pregnant women with a MCA-PSV under 1.5 MoM
throughout gestation. In our series, among pregnant
women with clinically significant antibodies, despite a
MCA-PSV lower than 1.5 MoMs, 15.6% of newborns re-
quired postnatal exchange transfusion due to high biliru-
bin values. All of them had antibody titers above 1:128.
Therefore, in cases of clinically significant antibodies,
without maternal-fetal compatibility and with a titer > 1:
16, it is always advisable to deliver at a tertiary center re-
gardless of the MCA-PSV.
Earlier gestational age at the time of the first transfusion
correlates with a greater number of transfusions. In our
series, all fetuses with 3 or more transfusions had their
first transfusion before 28 weeks. On the other hand, most
adverse outcomes (posttransfusion death, pregnancy ter-
mination) occurred when the first transfusion was at an
early gestational age; therefore, this is the group of trans-
fused fetuses with higher risk, especially in the presence of
fetal hydrops, which is why it is important to anticipate
hydrops and severe anemia through proper follow-up
(ultrasound and titration of antibodies in indicated cases).
Broad use of the technique of intrauterine transfusion
has resulted in an overall survival rate of 96.7%, reaching
100% in nonhydropic fetuses receiving their first transfu-
sion after 28 weeks.
The risk of fetal anemia can be ruled out by the study
of the paternal phenotype. In the case of anti-Kell isoim-
munization, it is especially efficient, since it results in
routine gestational follow-up in 53% of the cases.
Determination of fetal antigen in amniotic fluid or mater-
nal blood does not depend on paternity and allows strict
monitoring only in gestations with a real risk of fetal
anemia. In our series, 20.3% of the studied cases with a risk
of fetal anemia, and with positive or unknown paternal
antigen, were able to undergo routine pregnancy control.
Clinical relevance
The findings of this study are clinically relevant in many
aspects. First, the IAT should be performed for all preg-
nant women, regardless of their RhD antigen status,
since non-anti-D antibodies can also lead to fetal
anemia. Second, determination of the paternal pheno-
type and fetal antigen status in maternal blood or amni-
otic fluid permits us to rule out cases at high risk for
fetal anemia, increasing the surveillance of these preg-
nancies and allowing routine follow up of the low risk
group, with good perinatal outcomes. Third, the figures
in this report provide useful information for the counsel-
ing of couples with isoimmunization.
Strengths and limitations
One of the strengths of this study is that it was carried out
in a center with a large level of experience in isoimmuni-
zation, blood transfusions and neonatal management,
yielding a high number of cases and good outcomes.
One of the limitations of the study is that over the
course of the lengthy study period there have been
changes to the protocol, mainly the introduction of fetal
antigen determination in maternal blood. Another limi-
tation is that the data on neonatal outcomes were in-
complete since those cases with low risk of fetal anemia
delivered at their centers of origin.
Conclusion
In conclusion, despite the anti-D prophylaxis policy,
anti-D remains the most frequent antibody in fetuses re-
quiring intrauterine transfusion. A classification of low
or high risk for fetal anemia, based on the type of anti-
body, paternal phenotype and fetal antigen, allows
follow-up of the pregnancy accordingly, with good peri-
natal outcomes in the low risk group. In the high-risk
group, adverse perinatal outcomes are related to high
MCA-PSV, hydrops and early gestational age at first
transfusion. Neonatal treatment is only required in high-
risk pregnancies with high antibody levels.
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